{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-22-000003","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.819853+00:00","generated_at":"2026-06-26T23:51:22.989181+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amphastar Q4 revenue $120.9M, GAAP EPS $0.39; full-year net income $62.1M","bullets":["Q4 net revenues $120.9M vs $95.9M in Q4 2020, up 26%; GAAP net income $19.8M vs loss of $6.3M.","Full-year net revenues $437.8M vs $349.8M in 2020; GAAP net income $62.1M vs $1.4M.","Adjusted non-GAAP diluted EPS $0.42 for Q4 and $1.37 for full year.","CEO cites continued growth of higher-margin products and expects pipeline milestones in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-22-000003","json":"https://secwatch.observer/filing/0001297184-22-000003.json","markdown":"https://secwatch.observer/filing/0001297184-22-000003.md","text":"https://secwatch.observer/filing/0001297184-22-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718422000003/0001297184-22-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718422000003/amph-20220310x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T23:51:22.989181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}